Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial

Nature and Science of Sleep study authors

Published in Nature and Science of Sleep

Methodology

Randomised, double-blind, placebo-controlled trial of magnesium bisglycinate over 4 weeks in healthy adults reporting poor sleep, with PSQI, sleep diaries and actigraphy endpoints.

Key Findings

In 155 healthy adults reporting poor sleep, 4 weeks of magnesium bisglycinate improved subjective sleep quality (PSQI) and reduced sleep-onset latency versus placebo, with improvements also seen in daytime tiredness; objective actigraphy differences were smaller and less consistent.

Conclusions

Magnesium bisglycinate modestly improved self-reported sleep quality and onset latency in poor sleepers over 4 weeks, an encouraging but short and industry-supported result.

Limitations

Short 4-week duration in a self-selected poor-sleeper sample without diagnosed insomnia; primary outcome self-reported and prone to expectation effects; baseline magnesium status not uniformly deficient; industry involvement in supply of the study product.